-
平臺(tái)編號(hào)：bio-68628
-
國(guó)際編號(hào)：HB-11766?
-
細(xì)胞信息： QCRL-3
-
規(guī)格：frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購(gòu)
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類(lèi)或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫(kù)為準(zhǔn)）
QCRL-3
是否是腫瘤細(xì)胞：0
物種來(lái)源：小鼠
數(shù)量：大量
運(yùn)輸方式：凍存運(yùn)輸
ATCC Number：HB-11766?
器官來(lái)源：脾
細(xì)胞形態(tài)：淋巴樣
免疫類(lèi)型：mouse IgG2a kappa
生長(zhǎng)狀態(tài)：懸浮生長(zhǎng)
規(guī)格：1mg Designations: QCRL-3
Depositors: ?Queen's University at Kingston
Isotype: mouse IgG2a kappa
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Organ: spleen
Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against a multidrug resistance protein (MRP)
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments:Animals were immunized with the multidrug resistant, small cell lung carcinoma, cell line H69AR (ATCC CRL-11351 ).
Spleen cells were fused with Sp2/0-Ag14 mouse myeloma cells.
The antibody reacts with MRP (multidrug resistance protein). MRP is a 190,000 integral membrane phosphoglycoprotein that is overexpressed in some drug-selected resistant cell lines and has been shown to cause multidrug resistance in transfected cells.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10(5) viable cells/ml.
Interval: Maintain cell density between 1 X 10(5) and 1 X 10(6) viable cells/ml.
Medium Renewal: Every 3 to 4 days
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
References: 49655: Deeley RG, Cole SP. Antibodies to a multidrug resistance protein. US Patent 6,063,621 dated May 16 2000
49661: Hipfner DR, et al. Detection of the M(r) 190,000 multidrug resistance protein, MRP, with monoclonal antibodies. Cancer Res. 54: 5788-5792, 1994. PubMed: 7954400
物種來(lái)源：小鼠
數(shù)量：大量
運(yùn)輸方式：凍存運(yùn)輸
ATCC Number：HB-11766?
器官來(lái)源：脾
細(xì)胞形態(tài)：淋巴樣
免疫類(lèi)型：mouse IgG2a kappa
生長(zhǎng)狀態(tài)：懸浮生長(zhǎng)
規(guī)格：1mg Designations: QCRL-3
Depositors: ?Queen's University at Kingston
Isotype: mouse IgG2a kappa
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Organ: spleen
Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against a multidrug resistance protein (MRP)
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments:Animals were immunized with the multidrug resistant, small cell lung carcinoma, cell line H69AR (ATCC CRL-11351 ).
Spleen cells were fused with Sp2/0-Ag14 mouse myeloma cells.
The antibody reacts with MRP (multidrug resistance protein). MRP is a 190,000 integral membrane phosphoglycoprotein that is overexpressed in some drug-selected resistant cell lines and has been shown to cause multidrug resistance in transfected cells.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10(5) viable cells/ml.
Interval: Maintain cell density between 1 X 10(5) and 1 X 10(6) viable cells/ml.
Medium Renewal: Every 3 to 4 days
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
References: 49655: Deeley RG, Cole SP. Antibodies to a multidrug resistance protein. US Patent 6,063,621 dated May 16 2000
49661: Hipfner DR, et al. Detection of the M(r) 190,000 multidrug resistance protein, MRP, with monoclonal antibodies. Cancer Res. 54: 5788-5792, 1994. PubMed: 7954400
